AstraZeneca CEO Pascal Soriot taps veteran cancer researcher Susan Galbraith for top oncology post
When Susan Galbraith joined the cancer R&D team at AstraZeneca in 2010, the pharma giant was undergoing a brutal takedown at the hands of analysts uniformly shaking their heads over one of the weakest pipelines among the majors. Both she and the company persevered, though, and went on to pioneer some of the most successful drug franchises in oncology.
Today, she takes her place as the new EVP of oncology research at AstraZeneca’s new research and development home in Cambridge, UK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.